What they say:
A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published, in the 15 November 2009 issue of the journal “Nature Medicine“[the number 1 journal in General Medicine with an I.F of 28.054], by Prof. Thistlethwaite PA, Li X and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Repurposing the H.Pyroli vaccine CTB-UE into a pulmonary arterial hypertension (PAH): CTB-UE, a Helicobacter Pyroli vaccine, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3
The significance of the study:
This study suggests, first the first time, Helicobacter Pyroli vaccine CTB-UE-based therapy, with detailed mechanistic insights, for curing pulmonary arterial hypertension.
CTB-UE vaccine, which contains mucosal adjuvant cholera toxin B subunit (CTB) and five cell epitopes from the H. pylori urease subunits,, has been shown to be effective in controlling infections caused by H. pylori. However, the mechanism of action remains largely unknown.
H.Pyroli vaccine CTB-UE, by increasing the expression of its target gene, it may decrease the expression of Notch3 and its target gene Hes-5 (Fig.1). Thereby, it may inhibit and promote, respectively, proliferation and differentiation of smooth muscle cells. And, thereby, prevent pulmonary hypertension (Figure 1). Thus, H.Pyroli CTB-UE vaccine, either alone or in combination with other drugs,” may be used to treat/cure pulmonary arterial hypertension (Fig. 2). Together, this study suggests that by vaccinating pulmonary hypertensive patients with H.Pyroli vaccine CTB-UE, one may prevent pulmonary arterial hypertension.
Figure 1. Mechanistic insights into how H.Pyroli vaccine CTB-UE functions as an anti-pulmonary arterial hypertensive vaccine. H.Pyroli CTB-UE vaccine may promote insulin sensitivity and protect against myocardial infarction, via up-regulation of reprogramming protein Lin-28
Figure 2. H.Pyroli vaccine CTB-UE may function as an anti-hyperglycemic agent through induction of Lin-28
Details of the research findings:
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed mechanistic information: How H.Pyroli CTB-UE vaccine decreases the expression of Notch3 and its target gene
Amount: $500#
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase and payment details, you may reach us at info@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Repurposing the H.Pyroli vaccine CTB-UE into a pulmonary arterial hypertension (PAH) vaccine: CTB-UE, a Helicobacter Pyroli vaccine, inhibits the development of pulmonary arterial hypertension via down-regulation of its target gene Notch3, 20/July/2018, 1.22 pm, Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite us, drop us a line at info@genomediscovery.org